Showing 491-500 of 1697 results for "".
Fatigue in Patients With Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/fatigue-in-patients-with-multiple-sclerosis/30212/Treating fatigue in patients with multiple sclerosis may significantly improve quality of life and requires a high index of suspicion for coexisting sleep disorders.Immunopathogenesis of Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/immunopathogenesis-of-multiple-sclerosis/30127/Disruption of immune tolerance, inflammation, and blood-brain–barrier breach lead to demyelination and axonal injury.Intracranial Atherosclerotic Disease
https://practicalneurology.com/diseases-diagnoses/stroke/intracranial-atherosclerotic-disease/30143/Neurologists need to be vigilant for this common cause of ischemic stroke, associated with the highest rates of recurrent stroke.Iatrogenic Hypoglossal Nerve Palsy
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/iatrogenic-hypoglossal-nerve-palsy/30684/- Migraine: A Rational Approach to Drug Selectionhttps://practicalneurology.com/diseases-diagnoses/headache-pain/0105-migraine-pdf/31505/Optimizing Migraine Management with Triptans: A Comprehensive OverviewThe landscape of acute migraine treatment has significantly expanded with the introduction of seven distinct triptan medications, offering healthcare professionals enhanced options for patient care. Triptans, all 5-HT1B/1D recepto
Oral Disease Modifying Therapy for MS: Important Considerations
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/oral-disease-modifying-therapy-for-ms-important-considerations/30827/The availability of an oral agent for MS may create a therapeutic dilemma for clinicians as they try to determine the role of new therapy in patient care.Resumption of Anticoagulant Therapy Following Ischemic and Hemorrhagic Strokes: Indications and Timing
https://practicalneurology.com/diseases-diagnoses/stroke/resumption-of-anticoagulant-therapy-following-ischemic-and-hemorrhagic-strokes-indications-and-timing/31965/Resumption of anticoagulant in ischemic stroke or intracranial hemorrhage should be individualized.Broadening the Net in Stroke Care
https://practicalneurology.com/diseases-diagnoses/stroke/broadening-the-net-in-stroke-care/30287/Parkinson's Disease: Disease Modifying Therapies Remain Elusive
https://practicalneurology.com/diseases-diagnoses/movement-disorders/parkinsons-disease-disease-modifying-therapies-remain-elusive/30604/Insights from Zoltan Mari, MDKeep the Insurance Profit, Reduce Taxes, Protect Assets: Own Your Own Insurance Company
https://practicalneurology.com/columns/practice-management/keep-the-insurance-profit-reduce-taxes-protect-assets-own-your-own-insurance-company/30716/